Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma

Chiang, Yin-Yin; Chou, Yi–Hong; Chang, Kai‐Ping; Liao, Chun‐Ta; Wu, Yao-Yu; Yap, Wing-Keen; Pai, Ping‐Ching; Chang, Joseph Tung-Chieh; Lin, Chien‐Yu; Fan, Kang‐Hsing; Huang, Bing‐Shen; Hung, Tsung Min; Tsang, Ngan‐Ming

doi:10.1186/s13014-020-01632-1

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, they found 5year OS to be 53.0%, 58.1% and 64.5% in the early missed RT, late missed RT and RT-as-planned groups, respectively (p=0.046). Early missed RT was independently associated with both poorer OS (p=0.006) and the occurrence of distant metastases (p=0.031) (38).…”

Section: Discussionmentioning

confidence: 99%

CisplatinVersusCarboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NASSIF

Wichmann

Strube

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: The implementation of a platinum-containing regimen is recommended for definitive and adjuvant therapy of patients with locally advanced head and neck tumour. We compared the conditions for the use of cisplatin or carboplatin/paclitaxel or for changing between these two regimens on a clinic-specific basis. Patients and Methods: We evaluated 150 patients with advanced head and neck squamous cell carcinoma who received simultaneous radiochemotherapy at our institution between 2012 and 2017. Chemotherapy with weekly doses of cisplatin (40 mg/m 2 , group 1) or, in cases of impaired renal and/or cardiac function, with weekly doses of carboplatin AUC2 and paclitaxel (45 mg/m 2 , group 2), was performed as a first-choice therapy. If toxicities occurred in group 1, treatment was switched to the carboplatin/paclitaxel regimen (group 3). Patient-and therapy-related parameters, toxicity and survival data were compared across groups. Results: We examined 99, 30, and 21 patients in each group who received at least 1 course of chemotherapy. Group 3 patients switched from cisplatin to carboplatin/paclitaxel after a median of 3 courses due to nephrotoxicity (95.2%). The target of at least 5 chemotherapy courses was most frequently achieved by patients in group 1 (69.7%), followed by group 3 (61.9%) and then group 2 (40.0%). Multivariate analysis revealed that patients who switched groups were more likely to be over 60 years old (p=0.021), undergo definitive radiochemotherapy (p=0.049) and develop higher nephrotoxicity (p=0.036) than group 1 patients. Outcomes did not differ between groups. Conclusion: When cisplatin application is contraindicated due to renal-or cardiotoxicity, carboplatin/paclitaxel is an appropriate option.In definitive and adjuvant radiochemotherapy (RCT) of locally advanced head and neck tumour patients, different chemotherapy (CTx) regimens are applied depending on specific clinical criteria. The guideline recommendation foresees the utilization of a platinum-containing regimen (1, 2), with cisplatin being the most commonly advocated and used at a cumulative dose of at least 200 mg/m 2 (3, 4). At our institution, we prefer weekly administration of cisplatin 40 mg/m 2 body surface area (BSA) (5). We observed an increased incidence of renal toxicity following administration of cisplatin, as did other studies (6, 7). Some patients have initially high renal parameters or cardiac comorbidities, disqualifying them for cisplatin use. In these circumstances, a carboplatin-based regimen is administered (8, 9). Carboplatin, with its radiosensitizing properties and lower renal effect than cisplatin, qualifies under National Comprehensive Cancer Network (NCCN) guidelines as an effective alternative for patients for whom cisplatin is not appropriate. Phase II trials of carboplatin-oriented concurrent RCTs have shown complete response rates of 65.0%-70.0%, similar to those seen with cisplatin. Noronha et al. concluded that a carboplatin-based RCT is well tolerated by patients who are ineligible for cispla...

show abstract

Section: Discussionmentioning

confidence: 99%

CisplatinVersusCarboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NASSIF

Wichmann

Strube

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

“…Efeitos sistêmicos indiretos também podem se instalar em consequência da mucosite oral, tais como perda de massa corpórea e desnutrição. Pode-se considerar essas complicações como motivos de interrupção do tratamento ou de desistência do tratamento por parte do paciente, influenciando, ainda, o sucesso do tratamento geral e o prognóstico da doença (Elting et al, 2007;Mazzola et al, 2016;Chiang et al, 2020).…”

Section: Risco De Mucosite Oral Na Vmatunclassified

Toxicidade aguda em cavidade oral e glândulas salivares em pacientes submetidos à arcoterapia volumétrica modulada na região de cabeça e pescoço

Gobbi¹

View full text Add to dashboard Cite

Agradeço à Deus, por todas as bênçãos, À minha orientadora Luciana Corrêa, que com paciência, rigor e carinho me acolheu e cultivou o melhor de mim. Meu crescimento pessoal com essa experiência, devo a sua orientação, Á Fernanda de Paula Eduardo e Letícia Mello Bezinelli, por todo o apoio e pela oportunidade diária de aprendizado e crescimento, e cujo exemplo me serve de guia, À FOUSP, por toda a estrutura do curso de pós-graduação,

show abstract

Language barriers in head and neck cancer: Matched pair analysis of outcomes between non‐English speaking and English‐speaking patients

Chen

2024

Head & Neck

View full text Add to dashboard Cite

PurposeAs society grows in cultural diversity, an increasing proportion of patients are expected to be from non‐English speaking backgrounds. This study sought to compare the clinical outcomes between non‐English speakers and English speakers treated by radiation therapy for head and neck cancer.Methods and materialsSeventy‐five non‐English speaking patients with squamous cell carcinoma of the head and neck were matched to English‐speaking controls based on patient and disease variables; clinical outcomes were compared.ResultsNon‐English speaking patients had inferior 3‐year overall survival (64% vs. 77%, p = 0.02) and progression‐free survival (59% vs. 73%, p = 0.01) compared with the English‐speaking cohort. On logistical regression, non‐English‐speaking status was associated with a significantly increased risk of overall death (OR = 1.41; 95% CI, 1.09–1.92).ConclusionsPrognosis differed significantly between non‐English speaking and English‐speaking patients. Culturally tailored programs to address language barriers should be considered to ameliorate disparities in outcome.

show abstract

Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma

Cited by 5 publications

References 36 publications

CisplatinVersusCarboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

CisplatinVersusCarboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Toxicidade aguda em cavidade oral e glândulas salivares em pacientes submetidos à arcoterapia volumétrica modulada na região de cabeça e pescoço

Language barriers in head and neck cancer: Matched pair analysis of outcomes between non‐English speaking and English‐speaking patients

Contact Info

Product

Resources

About